DeAngelo, D J
George, T I
Linder, A
Langford, C
Perkins, C
Ma, J
Westervelt, P
Merker, J D
Berube, C
Coutre, S
Liedtke, M
Medeiros, B
Sternberg, D
Dutreix, C
Ruffie, P-A
Corless, C
Graubert, T J
Gotlib, J
Article History
Received: 25 April 2017
Revised: 2 July 2017
Accepted: 10 July 2017
First Online: 24 July 2017
Competing interests
: Dr DeAngelo/Dana Farber Cancer Institute has received funding to conduct the current trial; he has also received funding to conduct the trial of BLU-285 (Blueprint Medicines) in advanced SM. Dr George served on the Study Steering Committee for the Novartis-sponsored global trial and she has served on an advisory board and received honoraria from Novartis. She has also received honoraria from Blueprint Medicine and research funding from Allakos, Inc. The University of New Mexico has received funding for Dr George’s participation in the Novartis-sponsored global trial of midostaurin in advanced SM, the Seattle Genetics-sponsored trial of brentuximab vedotin in advanced SM and the Blueprint Medicine-sponsored trial of BLU-285 in advanced SM. Dr Graubert/Washington University received funding to conduct the current trial. Dr Gotlib served as Chairman of the Study Steering Committee for the Novartis-sponsored global trial of midostaurin in advanced SM, received funding to conduct this trial and the global trial and he has served on an advisory board and received honoraria from Novartis. Stanford has also received funding for Dr Gotlib’s participation in the following trials in advanced SM: BLU-285 (Blueprint Medicines), brentuximab vedotin (Seattle Genetics) and ibrutinib (Pharmacyclics).